Search Results 1321-1330 of 19357 for hemoglobin

1. A Study to Evaluate the Safety and Effectiveness of BMS-986036 (pegbelfermin) in Adults with Nonalcoholic Steatophepatitis (NASH) and Compensated Liver Fibrosis - Mayo Clinic

   Hemoglobin A1c ≥10%;; Fasting TGs > 500 mg/dL;; Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 according to the Modification of Diet in ...

2. A Study of Pacemakers to Treat Slow Heart Rate in Patients With Heart Failure - Mayo Clinic

   Severe anemia (Hemoglobin < 10 g/dL). Severe hepatic disease. Complex congenital heart disease. Listed for cardiac transplantation. Other class I ...

3. A Study to Evaluate Ulixertinib to Treat Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL;; Platelets ≥ 100 x 10^9 cells/L;; Absolute neutrophil count ≥ 1.5 x 10^9 cells/L). Adequate cardiac function: Left ventricular ...

4. Trial Using Keytruda as Initial Therapy in the Treatment of Advanced Mycosis Fungoides - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL or ≥ 5.6 mmol/L without transfusion or EPO dependency (within 7 days of assessment);; Serum total bilirubin ≤ 1.5 X ULN OR Direct ...

5. Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma - Mayo Clinic

   Hemoglobin ≥ 10 g/dL (RBC transfusion allowed); Not pregnant or nursing; Negative pregnancy test; Fertile patients must use contraception; No known HIV ...

6. Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL; Total bilirubin ≤ 1.5 x IULN; AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN, or ≤ 5.0 x IULN if due to liver involvement by tumor; Creatinine ...

7. RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC - Mayo Clinic

   - Hemoglobin ≥ 8 g/dL(transfusions allowed; however, patient must not be transfusion-dependent). 8. Has adequate hepatic function, including: - Total ...

8. A Study of Using Palbociclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive/ Human Epidermal Growth Factor Receptor 2 Negative Early Breast Cancer - Mayo Clinic

   Hemoglobin ≥ 10g/dL. Total serum bilirubin ≤ ULN; or total bilirubin ≤ 3.0 × ULN with direct bilirubin within normal range in patients with documented ...

9. A Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease - Mayo Clinic

   Subject has a history of diabetes mellitus type 1, or uncontrolled diabetes mellitus type 2 with hemoglobin A1c (HbA1c) > 9%, or is a diabetic subject with ...

10. A Study To Evaluate APG2575 Combined With Novel Therapeutic Regimens To Treat Subjects With Relapsed Or Refractory Multiple Myeloma And Immunoglobulin Light Chain Amyloidosis - Mayo Clinic

    Hemoglobin ≥ 8 g/dL without transfusion or growth factor support within 7 days of the first dose of study drug;; Platelet count ≥ 50 x 10^9/L without ...